ADHD is often thought of as a problem with focus: losing track in meetings, forgetting appointments, struggling to finish tasks.

A large new review suggests it’s also a matter of life and death. Across studies covering nearly 16 million people, people with ADHD died at a rate about 71% higher than people without it.

A review pooled 19 studies covering nearly 16 million people

Lucy Corrigan, Amber John and colleagues at the University of Liverpool, University College London, King’s College London and the charity ADHD UK carried out a systematic review and meta-analysis, published in JAMA Network Open.

A meta-analysis pools the results of many studies to get a more reliable overall estimate. The team searched six research databases and found 19 studies with 15.9 million participants, from the US, Canada, Sweden, Taiwan, the UK, Finland and Denmark. Most were large national health-register studies, and most were rated good quality.

They compared death rates for people with and without ADHD, by cause of death. They also looked at whether people with ADHD who took medication had different death rates from those who didn’t.

Death rates were higher from suicide, injuries and natural causes

Compared with people without ADHD, people with ADHD had:

  • 71% higher death rates from any cause
  • 89% higher rates of death by suicide
  • 55% higher rates of death from injuries, accidental or intentional
  • 27% higher rates of death from natural causes, such as illness

Among people with ADHD, those taking medication had a 25% lower death rate than those not taking it. That estimate came from just three studies.

“71% higher” compares death rates, not lifespans

These figures are relative risks. They compare death rates between groups over the same period, not lifespans.

So “71% higher” means that where about 10 people without ADHD die over a given period, roughly 17 people with ADHD die over the same period. (That’s our illustration of the ratio, not a figure from the paper.)

Many of these studies followed children and young adults, ages when deaths are rare. So the absolute risk for any one person remains low. The review didn’t pool absolute rates or estimate years of life lost.

Lapses of attention and impulsivity may add up to risk

The review measured death rates, not their causes in detail, so the explanations below are possibilities supported by other research rather than findings of this study.

Accidents. ADHD involves lapses of attention and acting before thinking. Most of the time this means a missed deadline or a lost key. But a momentary lapse while driving, cycling or crossing a road can be fatal. Imagine a driver who glances at a phone for two seconds: at 50 km/h, the car travels nearly 30 metres in that time.

Suicide. ADHD often comes with depression, anxiety and substance use, and impulsivity may make it harder to stop in a moment of crisis.

Health over time. Difficulty with planning and routine can make it harder to keep up healthy habits, take medication regularly or attend medical appointments, which may help explain the higher rate of deaths from illness.

Medication was linked to lower death rates, but the evidence is thin

The medication finding is encouraging but preliminary. It rests on three observational studies, and people who take medication may differ from those who don’t in other ways, such as getting better medical care overall.

Earlier research points in the same direction. A 2017 study in JAMA Psychiatry of more than 2.3 million Americans with ADHD compared the same people’s months on and off medication. Crash risk was lower in the months they took medication. Because each person was compared with themselves, that design rules out many differences between people.

The authors also note that evidence on medication is mixed, and that stimulant medications can have cardiovascular side effects. The review doesn’t show that medication extends life.

What the study doesn’t show

  • It’s all observational. The studies show associations, not that ADHD itself or medication directly causes the differences in death rates.
  • The results varied a lot. Heterogeneity, a measure of how much studies disagree, was extremely high for all-cause mortality: 98% on a scale where above 75% is considered high. The size of the risk differs widely between studies, even though the overall direction is clear.
  • ADHD was defined differently, from clinical diagnosis to self-report or trait questionnaires.
  • Few studies per cause. The all-cause estimate used 9 studies; suicide 5, injury 4, natural causes and medication 3 each.
  • Other conditions weren’t fully separated. Depression, substance use and social disadvantage often accompany ADHD and may explain part of the extra risk.
  • Peer reviewed, but the authors call for standardised methods and better control of confounding factors.

ADHD deserves to be treated as a health issue

It’s reasonable to take ADHD seriously as a health issue, not just a matter of concentration. That’s an implication of the findings, not something the review directly tested.

  • Seek assessment if you suspect you or someone close to you has ADHD, including in adulthood.
  • Discuss treatment options with a doctor. Medication is one option among several, and this review doesn’t prove it extends life.
  • Pay attention to injury risk, especially driving: minimise distractions and avoid driving when tired.
  • Watch for signs of depression or crisis. If you or someone you know is struggling, contact a health professional or a crisis line.

ADHD is more than a problem of focus

ADHD affects millions of adults, many of them undiagnosed. Seeing it only as a problem of focus can make it seem minor.

This review adds to evidence that it carries real risks, including suicide and injuries, and that recognising and treating it may help.

ADHD isn’t just about attention.

For some people, it can be a matter of survival.